DE3470744D1 - New camptothecin derivatives and process for preparing same - Google Patents

New camptothecin derivatives and process for preparing same

Info

Publication number
DE3470744D1
DE3470744D1 DE8484108257T DE3470744T DE3470744D1 DE 3470744 D1 DE3470744 D1 DE 3470744D1 DE 8484108257 T DE8484108257 T DE 8484108257T DE 3470744 T DE3470744 T DE 3470744T DE 3470744 D1 DE3470744 D1 DE 3470744D1
Authority
DE
Germany
Prior art keywords
substituted
ring
group
atom
camptothecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484108257T
Other languages
German (de)
English (en)
Inventor
Tadashi Miyasaka
Seigo Sawada
Kenichiro Nokata
Eiichi Sugino
Masahiko Mutai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Application granted granted Critical
Publication of DE3470744D1 publication Critical patent/DE3470744D1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE8484108257T 1983-07-14 1984-07-13 New camptothecin derivatives and process for preparing same Expired DE3470744D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58126946A JPS6019790A (ja) 1983-07-14 1983-07-14 新規なカンプトテシン誘導体

Publications (1)

Publication Number Publication Date
DE3470744D1 true DE3470744D1 (en) 1988-06-01

Family

ID=14947803

Family Applications (2)

Application Number Title Priority Date Filing Date
DE8484108257T Expired DE3470744D1 (en) 1983-07-14 1984-07-13 New camptothecin derivatives and process for preparing same
DE198484108257T Pending DE137145T1 (de) 1983-07-14 1984-07-13 Camptothecin-derivate und verfahren zu deren herstellung.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE198484108257T Pending DE137145T1 (de) 1983-07-14 1984-07-13 Camptothecin-derivate und verfahren zu deren herstellung.

Country Status (8)

Country Link
US (1) US4604463A (enExample)
EP (1) EP0137145B1 (enExample)
JP (1) JPS6019790A (enExample)
AT (1) ATE33839T1 (enExample)
CA (1) CA1235415A (enExample)
DE (2) DE3470744D1 (enExample)
LU (1) LU90074I2 (enExample)
NL (1) NL980026I2 (enExample)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106742A (en) * 1987-03-31 1992-04-21 Wall Monroe E Camptothecin analogs as potent inhibitors of topoisomerase I
US5053512A (en) * 1987-04-14 1991-10-01 Research Triangle Institute Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
US5122526A (en) * 1987-03-31 1992-06-16 Research Triangle Institute Camptothecin and analogs thereof and pharmaceutical compositions and method using them
US4981968A (en) * 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5227380A (en) * 1987-03-31 1993-07-13 Research Triangle Institute Pharmaceutical compositions and methods employing camptothecins
US4894456A (en) * 1987-03-31 1990-01-16 Research Triangle Institute Synthesis of camptothecin and analogs thereof
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5049668A (en) * 1989-09-15 1991-09-17 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin analogs
US5122606A (en) * 1987-04-14 1992-06-16 Research Triangle Institute 10,11-methylenedioxy camptothecins
US5180722A (en) * 1987-04-14 1993-01-19 Research Triangle Institute 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
US4939255A (en) * 1987-06-24 1990-07-03 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic camptothecin derivatives
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) * 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
US5225404A (en) * 1989-11-06 1993-07-06 New York University Methods of treating colon tumors with tumor-inhibiting camptothecin compounds
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5658920A (en) * 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
US6407115B1 (en) * 1991-01-16 2002-06-18 Daiichi Pharmaceutical Co., Ltd. Hexa-cyclic compound
ATE247471T1 (de) 1991-11-15 2003-09-15 Smithkline Beecham Corp Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
US5446047A (en) * 1992-07-23 1995-08-29 Sloan-Kettering Institute For Cancer Research Camptothecin analogues
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
GB9402934D0 (en) * 1994-02-16 1994-04-06 Erba Carlo Spa Camptothecin derivatives and process for their preparation
US5468754A (en) * 1994-04-19 1995-11-21 Bionumerik Pharmaceuticals, Inc. 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
US5597829A (en) * 1994-05-09 1997-01-28 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of camptothecin and methods for uses thereof
US5604233A (en) * 1994-04-28 1997-02-18 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5614529A (en) * 1994-09-22 1997-03-25 Research Triangle Institute Inhibition of plasmodia parasites by camptothecin compounds
US6177439B1 (en) 1995-06-06 2001-01-23 Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin
US6214836B1 (en) 1995-06-06 2001-04-10 Dr. Reddy's Research Foundation Water soluble analogues of 20(S)-camptothecin
EP0835303A4 (en) * 1995-06-07 2000-09-13 Univ Jefferson Anti-fungal agents and methods of identifying and using the same
AU7732996A (en) * 1995-11-22 1997-06-11 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
US6395541B1 (en) 1996-05-23 2002-05-28 The Rockefeller University Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
KR100516593B1 (ko) * 1996-08-19 2005-09-22 바이오누머릭 파마슈티칼스, 인코포레이티드 고 친유성 캠프토테신 유도체
WO1998037892A1 (en) * 1997-02-27 1998-09-03 Pharmacia & Upjohn Company Tamoxifen as a therapy to reduce irinotecan hydrochloride-induced diarrhea
JP3046258B2 (ja) * 1997-04-11 2000-05-29 株式会社ヤクルト本社 １−クロロカルボニル−４−ピペリジノピペリジンまたはその塩酸塩の製造方法
ID23424A (id) 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6214821B1 (en) 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
HUP0103314A3 (en) * 1998-08-05 2002-07-29 Aventis Pharma Sa Use of camptothecin derivatives, with reduced gastrointestinal toxicity
US6043367A (en) * 1998-09-30 2000-03-28 Roffler; Steve Proactive antitumor compounds
US20050281821A1 (en) * 1999-01-06 2005-12-22 Flavia Pernasetti Method and composition for angiogenesis inhibition
US6228855B1 (en) 1999-08-03 2001-05-08 The Stehlin Foundation For Cancer Research Aromatic esters of camptothecins and methods to treat cancers
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6159935A (en) * 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
CA2401191C (en) 2000-02-28 2006-05-02 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
AR027687A1 (es) * 2000-03-22 2003-04-09 Yakult Honsha Kk Procedimiento para preparar camptotecina
AU2001261474B2 (en) 2000-05-15 2006-03-09 Celgene Corporation Compositions and methods for the treatment of cancer
EP1286671B1 (en) * 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
AU1602902A (en) 2000-10-27 2002-05-06 Aventis Pharma Sa A combination comprising camptothecin and a stilbene derivative for the treatment of cancer
US7390885B2 (en) * 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) * 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
JP2005525367A (ja) * 2002-03-01 2005-08-25 フアルマシア・イタリア・エツセ・ピー・アー 塩酸イリノテカンの結晶多形
CN1649627A (zh) * 2002-04-26 2005-08-03 法赫马西亚及普强有限公司 用于治疗、预防或延迟肿瘤发生的方法和组合物
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
CN100363366C (zh) * 2002-06-27 2008-01-23 中国科学院上海药物研究所 一类喜树碱衍生物及制备方法
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US20040186160A1 (en) * 2002-12-13 2004-09-23 Sugen, Inc. Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors
US7151179B2 (en) 2003-05-12 2006-12-19 Scinopharm Taiwan, Ltd. Process for the preparation of 7-alkyl-10-hydroxy-20(S)-camptothecin
US7067666B2 (en) * 2003-06-27 2006-06-27 Research Triangle Institute 7-substituted camptothecin and camptothecin analogs and methods for producing the same
CZ299329B6 (cs) * 2003-08-26 2008-06-18 Pliva-Lachema A.S. Zpusob výroby 7-ethyl-10-[ 4-(1-piperidino)-1-piperidino]karbonyloxykamptothecinu
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CZ299593B6 (cs) * 2003-12-16 2008-09-10 Pliva-Lachema A. S. Zpusob výroby 7-ethyl-10-hydroxykamptothecinu
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
DE602005024923D1 (de) * 2004-02-13 2011-01-05 Yakult Honsha Kk Wässrige lösung mit einem camptothecin
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
US20050267141A1 (en) * 2004-05-28 2005-12-01 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives
KR100889139B1 (ko) 2004-06-01 2009-03-17 테루모 가부시키가이샤 이리노테칸 제제
US20050272757A1 (en) * 2004-06-04 2005-12-08 Phytogen Life Sciences Inc. Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
EP3085361A1 (en) * 2004-09-07 2016-10-26 Biocompatibles UK Limited Compositions comprising camptothecins in microspheres
US7897772B2 (en) 2004-10-01 2011-03-01 Kabushiki Kaisha Yakult Honsha Acid addition salt of irinotecan
US7205385B2 (en) * 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
CN101146532B (zh) 2005-01-21 2012-05-09 阿斯泰克斯治疗有限公司 药物化合物
WO2006082053A1 (en) * 2005-02-02 2006-08-10 Heidelberg Pharma Gmbh 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
WO2006082279A1 (en) * 2005-02-07 2006-08-10 Fermion Oy Process for the manufacturing of 7-ethyl-10-hydroxy camptothecin
CA2591071C (en) * 2005-02-08 2014-04-29 Fermion Oy Process for producing [1,4'] bipiperidinyl-1'-carbonyl chloride or hydrochloride thereof
PL1928883T3 (pl) 2005-02-08 2014-03-31 Fermion Oy Sposób otrzymywania chlorowodorku irynotekanu
WO2006096458A2 (en) * 2005-03-04 2006-09-14 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
US7994186B2 (en) * 2005-04-18 2011-08-09 Kabushiki Kaisha Yakult Honsha Pharmaceutical compositions containing camptothecins
US7767200B2 (en) * 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
ZA200800907B (en) * 2005-07-18 2010-04-28 Bipar Sciences Inc Treatment of cancer
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
US7608740B2 (en) * 2005-08-03 2009-10-27 Avra Laboratories Pvt. Ltd Method of synthesizing key intermediates for the production of camptothecin derivatives
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
EP2082741A1 (en) 2005-09-20 2009-07-29 Scinopharm Singapore Pte, Ltd. Novel crystal form of irinotecan hydrochloride
US7875602B2 (en) * 2005-10-21 2011-01-25 Sutter West Bay Hospitals Camptothecin derivatives as chemoradiosensitizing agents
EP1803725A1 (en) 2005-12-13 2007-07-04 W.C. Heraeus GmbH Methods for preparing irinotecan
CN1982313B (zh) * 2005-12-13 2010-12-01 深圳市天和医药科技开发有限公司 10位取代基上含多个有机羧酸基团的喜树碱化合物及其制法与组合物
US20070208050A1 (en) * 2006-02-24 2007-09-06 Palle Venkata Raghavendra Acha Process for preparing irinotecan
CN101033230B (zh) * 2006-03-10 2010-12-08 中国科学院上海药物研究所 一类喜树碱衍生物及其应用
AU2007232206B2 (en) * 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
JP2008081492A (ja) 2006-08-31 2008-04-10 Banyu Pharmaceut Co Ltd オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CN101534836B (zh) 2006-09-05 2011-09-28 彼帕科学公司 Parp抑制剂在制备治疗肥胖症的药物中的用途
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008035229A2 (en) * 2006-09-22 2008-03-27 Labopharm, Inc. Compositions and methods for ph targeted drug delivery
EA200970353A1 (ru) * 2006-10-06 2009-10-30 Такеда Фармасьютикал Компани Лимитед Комбинированное лекарственное средство
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
US20090062323A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched irinotecan
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
CA2720184C (en) 2008-03-31 2017-07-18 Boston Medical Center Corporation Predictive marker for topoisomerase i inhibitors
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2010218781A1 (en) 2009-02-25 2011-07-28 Msd K.K. Pyrimidopyrimidoindazole derivative
WO2010101734A1 (en) 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
EP2896632B1 (en) 2009-11-13 2017-10-25 Daiichi Sankyo Europe GmbH Material and methods for treating or preventing HER-3 associated diseases
US8546573B2 (en) 2009-11-18 2013-10-01 Cadila Healthcare Limited Process for the preparation of 7-ethyl-10-[4-(1-piperidino)-1-piperdino] carbonyloxy-camptothecin hydrochloride trihydrate
PT2501413T (pt) * 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8530444B2 (en) * 2010-06-01 2013-09-10 Aposense Ltd. Pharmaceutical compounds
WO2012018404A2 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
WO2012087943A2 (en) 2010-12-20 2012-06-28 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
WO2013093931A2 (en) 2011-09-19 2013-06-27 Sun Pharma Advanced Research Company Ltd. Novel prodrugs of phenolic drugs
DK2750683T4 (da) 2011-10-03 2021-04-12 Croda Int Plc Nanopartikler, fremgangsmåde til fremstilling og anvendelse deraf som bærer for amfipatiske eller hydrofobe molekyler inden for medicin, herunder cancerbehandling, og i fødevarerelaterede forbindelser
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
WO2014070233A1 (en) 2012-10-29 2014-05-08 Boston Medical Center Corporation Brca1 mutations as predictive markers for topoisomerase i inhibitors
CN103848840A (zh) * 2012-12-03 2014-06-11 中国人民解放军军事医学科学院毒物药物研究所 喜树碱衍生物及其医药用途
CN103864810A (zh) * 2012-12-07 2014-06-18 天津科技大学 一种新颖的10-羟基喜树碱10位衍生物制备方法及其在抗肿瘤药物中的应用
KR101847252B1 (ko) 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
JP6002835B2 (ja) 2013-03-27 2016-10-05 大鵬薬品工業株式会社 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤
AR095962A1 (es) 2013-04-01 2015-11-25 Moreinx Ab Nanopartículas, compuestas de esterol y saponina de quillaja saponaria molina, proceso para preparación y uso de las mismas como portadores para moléculas anfipáticas o hidrófobas en el campo de la medicina incluyendo tratamiento de cáncer y compuestos relacionados con alimentos
EP2881396A1 (en) * 2013-12-03 2015-06-10 Synbias Pharma AG Method for the synthesis of irinotecan
JP6704345B2 (ja) 2014-01-17 2020-06-03 オンコラル ファーマ エーピーエス 癌治療のためのイリノテカンの固体経口剤形
EA035674B1 (ru) 2014-07-18 2020-07-24 Санофи Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
WO2016123143A1 (en) 2015-01-26 2016-08-04 The University Of Chicago CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
CN107683289B (zh) 2015-01-26 2021-08-06 芝加哥大学 IL13Rα2结合剂和其在癌症治疗中的用途
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
WO2016203352A2 (en) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions and methods for the treatment of cancer
WO2016203337A2 (en) * 2015-06-14 2016-12-22 Mohan M Alapati Compositions and methods for the treatment of cancer
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
JP7042739B2 (ja) 2015-08-20 2022-03-28 イプセン バイオファーム リミティド 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法
TW202400181A (zh) 2015-08-21 2024-01-01 英商益普生生物製藥有限公司 使用包含微脂伊立替康(irinotecan)及奧沙利鉑(oxaliplatin)之組合療法治療轉移性胰臟癌的方法
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
EP4647126A3 (en) 2015-10-16 2026-02-11 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
US9980953B2 (en) * 2016-09-26 2018-05-29 Chong Kun Dang Pharmaceutical Corp. Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a VDA and topoisomerase inhibitor
CN110402163A (zh) 2016-11-02 2019-11-01 易普森生物制药有限公司 使用包括脂质体伊立替康、奥沙利铂、5-氟尿嘧啶(和甲酰四氢叶酸)的组合疗法治疗胃癌
CN108570057A (zh) * 2017-03-13 2018-09-25 烟台药物研究所 一种合成7-乙基-10-羟基喜树碱的方法
CA3071599A1 (en) 2017-08-07 2019-02-14 Amgen Inc. Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti pd-l1 antibody and an oncolytic virus
TW202002952A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療胰臟癌之abbv-621與抗癌劑之組合
WO2019178438A1 (en) 2018-03-15 2019-09-19 Abbvie Inc. Abbv-621 in combination with anti-cancer agents for the treatment of cancer
EP3669890A1 (en) 2018-12-18 2020-06-24 Croda International PLC Filamentous nanoparticles having vaccine adjuvant effect
US20220177583A1 (en) 2019-03-20 2022-06-09 The Regents Of The University Of California Claudin-6 bispecific antibodies
DK3941946T3 (da) 2019-03-20 2025-03-24 Univ California Claudin-6-antistoffer og lægemiddelkonjugater
EP3952841A1 (en) 2019-04-09 2022-02-16 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
JP2022530241A (ja) 2019-04-30 2022-06-28 インスチトゥート デ メディシーナ モリクラール ジョアン ロボ アントゥネス Ｃｄｋ阻害剤と組み合わせたｒａｎｋ経路阻害剤
EP3962521A1 (en) 2019-05-02 2022-03-09 University of Florida Research Foundation, Inc. Compositions for treatment of diffuse intrinsic pontine glioma
JP7763666B2 (ja) 2019-06-24 2025-11-04 アムジェン インコーポレイテッド 癌治療のためのＳＩＲＰγの阻害
CN111171077A (zh) * 2020-01-19 2020-05-19 上海交通大学医学院附属仁济医院 喜树碱衍生物及其制备方法和应用
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
IL312728A (en) 2021-11-30 2024-07-01 Daiichi Sankyo Co Ltd Protease-cleavable masked antibodies
TW202342106A (zh) 2022-02-09 2023-11-01 日商第一三共股份有限公司 環境應答性遮蔽抗體及其利用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894029A (en) * 1971-08-26 1975-07-08 Basf Ag Production of camptothecin and camptothecin-like compounds
JPS5198300A (en) * 1975-02-20 1976-08-30 Kanputoteshin oyobi sonoruijitaino seizoho
US4399282A (en) * 1979-07-10 1983-08-16 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives
US4399276A (en) * 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) * 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154583A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
JPS58154584A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd ５位ヒドロキシ置換カンプトテシン誘導体の製造法
JPS58154582A (ja) * 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS5951289A (ja) * 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体

Also Published As

Publication number Publication date
US4604463A (en) 1986-08-05
JPH034077B2 (enExample) 1991-01-22
JPS6019790A (ja) 1985-01-31
LU90074I2 (fr) 1997-08-21
EP0137145A1 (en) 1985-04-17
NL980026I1 (nl) 1998-11-02
NL980026I2 (nl) 1999-02-01
CA1235415A (en) 1988-04-19
EP0137145B1 (en) 1988-04-27
ATE33839T1 (de) 1988-05-15
DE137145T1 (de) 1985-11-21

Similar Documents

Publication Publication Date Title
DE3470744D1 (en) New camptothecin derivatives and process for preparing same
ATE89559T1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
KR950014097A (ko) 피페라진 유도체
EP0163599A3 (en) Pyrimidopyrimidine derivatives, processes for producing them, pharmaceutical compositions containing them and their use as anti-allergic agents
GB1303081A (enExample)
DE3473763D1 (en) Novel 4'-demethyl-4-epipodophyllotoxin derivatives, a process for their preparation and their use as medicaments
KR850005829A (ko) 2-시아노벤즈이미다졸 유도체의 제조방법
SE8405188D0 (sv) Platina komplex
ZA826755B (en) Substituted phenylsulfonylurea derivatives,a process for their preparation and their use as herbicides,and new intermediate products for their preparation
AU547792B2 (en) Pyrimido(5,4-d)pyrimidines
CH614448A5 (en) Process for the preparation of novel tertiary amines and their acid addition salts, and compounds thus prepared
ATE31414T1 (de) 8-substituierte pyrrolizidin-derivate und deren verwendung.
IE822330L (en) 2,2-disubstituted-ethylamines
DE3372095D1 (en) Novel phenylpiperazine derivatives and process for producing the same
HUT58270A (en) Process for producing amine derivatives and pharmaceutical compositions containing them
ATE148128T1 (de) Anthracyclinglycosid-derivate und verfahren zu ihrer herstellung
CA2056334A1 (en) Process for producing benzylphthalazinone derivatives and salts thereof
GB1363415A (en) Bis-pyridyl amine compounds
GB1507414A (en) Hydantoin derivatives
KR920700215A (ko) 비스(1,2-디아릴-1,2-에틸렌디티오레이토)니켈-기재 착물의 제조방법
SE7413858L (enExample)
YU195185A (en) Process for preparing derivatives of aminobenzamide
ES488388A1 (es) Procedimiento de preparacion de derivados hidroxilados del tiazol
GB1456525A (en) Process for the manufacture of alkanolamine derivatives
GB1374339A (en) Aminoquinoline derivatives and their production

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
V448 Application of spc

Free format text: PRODUCT NAME: IRINOTECAN-HYDROCHLORID-TRIHYDRAT; REGISTRATION NO/DATE: 43289.00.00, 43290.00.00; 19980806

Spc suppl protection certif: 199 75 010

Filing date: 19990202

V457 Spc granted

Free format text: PRODUCT NAME: IRINOTECAN-HYDROCHLORID-TRIHYDRAT; REGISTRATION NO/DATE: 43289.00.00, 43290.00.00; 19980806

Spc suppl protection certif: 199 75 010

Filing date: 19990202

V464 Spc expired

Free format text: PRODUCT NAME: IRINOTECAN-HYDROCHLORID-TRIHYDRAT; REGISTRATION NO/DATE: 43289.00.00, 43290.00.00; 19980806

Spc suppl protection certif: 199 75 010

Filing date: 19990202

R081 Change of applicant/patentee

Owner name: KABUSHIKI KAISHA YAKULT HONSHA, JP

Free format text: FORMER OWNER: KABUSHIKI KAISHA YAKULT HONSHA, TOKIO/TOKYO, JP

Spc suppl protection certif: 19975010

Filing date: 19990202

Expiry date: 20040714

Extension date: 20090713

Owner name: KABUSHIKI KAISHA YAKULT HONSHA, 1-19, HIGASHIS, JP

Free format text: FORMER OWNER: KABUSHIKI KAISHA YAKULT HONSHA, TOKIO/TOKYO, JP

Spc suppl protection certif: 19975010

Filing date: 19990202

Expiry date: 20040714

Extension date: 20090713

R082 Change of representative

Free format text: PRODUCT NAME: IRINOTECAN-HYDROCHLORID-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 43289.00.00 43290.00.00 19980806 FIRST REGISTRATION: FRANKREICH 558 822.2 558 823.9 558 824.5 558 825.1 19950505

Spc suppl protection certif: 19975010

Filing date: 19990202

Expiry date: 20040714

Representative=s name: VOSSIUS & PARTNER, DE

Extension date: 20090713

Free format text: PRODUCT NAME: IRINOTECAN-HYDROCHLORID-TRIHYDRAT; NAT. REGISTRATION NO/DATE: 43289.00.00 43290.00.00 19980806 FIRST REGISTRATION: FRANKREICH 558 822.2 558 823.9 558 824.5 558 825.1 19950505

Spc suppl protection certif: 19975010

Filing date: 19990202

Expiry date: 20040714

Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE

Extension date: 20090713